CDK4 and neoplasm: Additionally, inhibition of the PAM pathway has been found to increase cyclin D1 and CDK4/6 activity, which promotes proliferative cell cycling and can either increase sensitivity to CDK4/6 inhibition or restore sensitivity in tumor cells that have become resistant to CDK4/6 inhibition (9).